[go: up one dir, main page]

IL147123A0 - Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies - Google Patents

Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies

Info

Publication number
IL147123A0
IL147123A0 IL14712300A IL14712300A IL147123A0 IL 147123 A0 IL147123 A0 IL 147123A0 IL 14712300 A IL14712300 A IL 14712300A IL 14712300 A IL14712300 A IL 14712300A IL 147123 A0 IL147123 A0 IL 147123A0
Authority
IL
Israel
Prior art keywords
hla
soluble forms
treating inflammatory
compositions containing
inflammatory skin
Prior art date
Application number
IL14712300A
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Publication of IL147123A0 publication Critical patent/IL147123A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns a composition consisting essentially of at least a soluble form of HLA-G and at least an acceptable pharmaceutical carrier for preparing a medicine for treating inflammatory pathological conditions of the skin. The invention also concerns a method for obtaining soluble forms of HLA-G and antibodies directed against said soluble forms.
IL14712300A 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies IL147123A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (en) 1999-06-18 1999-06-18 USE OF COMPOSITIONS CONTAINING SOLUBLE FORMS OF HLA-G IN THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS AND THEIR METHOD OF OBTAINING
PCT/FR2000/001670 WO2000078337A1 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies

Publications (1)

Publication Number Publication Date
IL147123A0 true IL147123A0 (en) 2002-08-14

Family

ID=9546968

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14712300A IL147123A0 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
IL147123A IL147123A (en) 1999-06-18 2001-12-16 Use of a composition consisting of at least one soluble form of hla- g for preparing a medicinal product for treating inflammatory pathological skin conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL147123A IL147123A (en) 1999-06-18 2001-12-16 Use of a composition consisting of at least one soluble form of hla- g for preparing a medicinal product for treating inflammatory pathological skin conditions

Country Status (10)

Country Link
EP (1) EP1189627B1 (en)
JP (1) JP2003508351A (en)
AT (1) ATE251911T1 (en)
CA (1) CA2377519C (en)
DE (1) DE60005952T8 (en)
DK (1) DK1189627T3 (en)
ES (1) ES2206286T3 (en)
FR (1) FR2794977B1 (en)
IL (2) IL147123A0 (en)
WO (1) WO2000078337A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (en) * 2000-06-13 2004-04-02 Commissariat Energie Atomique NEW ISOFORM OF HLA-G AND ITS APPLICATIONS
WO2007011044A1 (en) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Pharmaceutical composition comprising disulfide-linked hla-g dimer and process for production of disulfide-linked hla-g dimer
MX2009004925A (en) 2006-11-15 2009-05-19 Basf Se Process for producing flexible polyurethane foams.
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2264067A1 (en) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
DK2575881T3 (en) * 2010-05-28 2017-01-09 Inst Nat Sante Rech Med Specific anti-CD160-antibodies for the treatment of eye diseases on the basis of neoangiogenesis
US20200157175A1 (en) 2017-05-23 2020-05-21 Julius-Maximilians-Universität Würzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
MA56388A (en) 2019-06-27 2022-05-04 Crispr Therapeutics Ag USE OF CHEMERA ANTIGEN RECEPTOR T LYMPHOCYTES AND NK CELL INHIBITORS FOR THE TREATMENT OF CANCER
WO2021005001A1 (en) * 2019-07-05 2021-01-14 Intellexon Gmbh Hla-h in medicine and diagnostics
EP4171585A1 (en) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (en) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcripts of the HLA-G class I MHC gene and their applications.
JPH11503320A (en) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア HLA-G detection antibody
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (en) * 1997-02-21 2004-05-07 Commissariat Energie Atomique EUKARYOTIC CELLS EXPRESSING AT THEIR SURFACE AT LEAST ONE ISOFORM OF HLA-G AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
ES2206286T3 (en) 2004-05-16
JP2003508351A (en) 2003-03-04
ATE251911T1 (en) 2003-11-15
CA2377519A1 (en) 2000-12-28
DK1189627T3 (en) 2004-02-16
DE60005952D1 (en) 2003-11-20
IL147123A (en) 2010-06-30
FR2794977B1 (en) 2003-10-31
CA2377519C (en) 2011-09-27
DE60005952T8 (en) 2004-11-04
FR2794977A1 (en) 2000-12-22
WO2000078337A1 (en) 2000-12-28
EP1189627B1 (en) 2003-10-15
EP1189627A1 (en) 2002-03-27
DE60005952T2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
IL127581A0 (en) Crystal form i of clarithromycin
PL353246A1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
MY133996A (en) Compounds for the treatment of ischemia
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
GB2357036B (en) Process for the preparation of dental prosthesis
GB9907571D0 (en) Compounds
MY120237A (en) Method for the synthesis of quinoline derivatives
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
UA32598C2 (en) Method for obtaining of carbamazepin dosage form
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
HUP0104928A3 (en) Pharmaceutical compositions comprising micronised colistin sulphomethate natrium, process for their preparation and their use
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
GB9919597D0 (en) Methods and compositions for diagnosis of hepatoma
HU9800835D0 (en) Pharmaceutical composition for treatment diseases causing by ascophaera apis